SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference on ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Tandem Diabetes Care has already proven that its closed-loop system for automated insulin delivery can improve the amount of time spent in range for people of all ages with Type 1 diabetes, but a new ...
The FDA approved its first automatic insulin dosing system designed to deliver correction boluses as well as adjust background insulin levels to help prevent bouts of high and low blood sugar in ...
A new software system that will let people with diabetes customize their treatment and automatically adjust their insulin levels was just approved for use by the Food and Drug Administration. It will ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results